In the competitive landscape of biopharma, the ability to rapidly scale manufacturing capacity for a promising late-stage therapy can define a company's commercial success. This was precisely the challenge facing a mid-sized biotech firm we'll refer to as BioVertex Therapeutics. With a novel biologic poised for Phase III trials and anticipated market approval, BioVertex needed a new, fully...